



Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool

October 27, 2022

Men Can Document Their Penile Curvature, Complete a Self-Assessment Questionnaire, Learn About Peyronie's Disease and Find a Provider Through the App

- Peyronie's Disease assessment and educational features are meant to empower men with knowledge of the condition and an understanding of their own penile curvature
- App to be unveiled to urologists / sexual medicine specialists and presented as an oral presentation at the 23rd Annual Fall Scientific Meeting of SMSNA

DUBLIN and BURNSVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) and the Sexual Medicine Society of North America (SMSNA) announced today the launch of a Peyronie's Self-Assessment application, available now in the [App Store](#) and [Google Play](#). Peyronie's Disease (PD) is a men's health condition that may affect 1 in 10 men and can lead to a curvature deformity with a plaque that can be felt in the penis.



Men who download the free app may use it to:

- Learn more about PD
- Complete a self-assessment questionnaire on the signs and symptoms of PD
- Document their degree of curvature deformity with a 3D scan and a 2D image
- Locate a healthcare provider near them

The app is not a diagnostic tool, but men can share the results with their urologist to help the physician evaluate symptoms.

"For many patients with PD, the condition feels too intimate or embarrassing to discuss with a doctor," said Gregory Broderick, M.D., founding member of SMSNA, member of the SMSNA Foundation Board of Directors and an author of the app presentation. "The new PD app can give men the facts they may need to help overcome that barrier and speak with knowledge and even confidence about their curvature to a urologist."

"The journey to treatment for men with PD can take upward of seven years," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "We hope that by putting educational material and a documentation tool literally in men's hands, they can feel more empowered to take control of their symptoms and talk to a urologist about their curvature."

The Peyronie's Self-Assessment app will be unveiled during the 23rd Annual Fall Scientific Meeting of SMSNA, taking place October 27-30 in Miami, FL, via an oral presentation on Saturday and a medical booth co-hosted by Endo and SMSNA.

Questionnaires are confidential, and scans are stored on the mobile device, but only within the app itself. The app does not share information with any outside party, unless the user chooses to send results to a urologist, and all data will be permanently deleted when the app is deleted from a device.

About Peyronie's Disease

Peyronie's Disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be painful during arousal and intimacy. PD can affect as many as 1 in 10 men in the U.S., but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.

About Endo

Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. [Learn more](#)

at www.endo.com or connect with us on [LinkedIn](#).

About SMSNA

Established in 1994, the Sexual Medicine Society of North America (SMSNA) is a not-for-profit organization of physicians, researchers, and other allied healthcare professionals committed to advancing the field of sexual medicine. SMSNA for Patients was established as SexHealthMatters in 2010 to provide information on a broad range of sexual health conditions. Learn more at www.smsna.org.

Cautionary Note Regarding Forward-Looking Statements

Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation, including, but not limited to, the statements by Drs. Broderick and Tursi, any statements relating to the application launch and any other statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the Company's strategy; risks and uncertainties associated with Chapter 11 proceedings; the negative impacts on the Company's businesses as a result of filing for and operating under Chapter 11 protection; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results while in Chapter 11 proceedings; the Company's ability to discharge claims in Chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in Chapter 11 proceedings; the Company's ability to conduct business as usual; the Company's ability to continue to serve customers, suppliers and other business partners at the high level of service and performance they have come to expect from the Company; the Company's ability to continue to pay employees, suppliers and vendors; the ability to control costs during Chapter 11 proceedings; adverse litigation; the risk that the Company's Chapter 11 cases may be converted to cases under Chapter 7 of the Bankruptcy Code; the Company's ability to secure operating capital; the Company's ability to take advantage of opportunities to acquire assets with upside potential; the Company's ability to execute on its strategic plan to pursue, evaluate and close an asset sale of the Company's businesses pursuant to Section 363 of the U.S. Bankruptcy Code; the impact of competition, including the loss of exclusivity and generic competition for VASOSTRICT[®]; our ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our ability to attract and retain key personnel; our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness; our ability to incur additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or general corporate or other purposes; our ability to refinance our indebtedness; a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs or repay indebtedness; supply chain interruptions or difficulties; changes in competitive or market conditions; changes in legislation or regulatory developments; our ability to obtain and maintain adequate protection for our intellectual property rights; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; our ability to integrate any newly acquired products into our portfolio and achieve any financial or commercial expectations; the impact that known and unknown side effects may have on market perception and consumer preference for our products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of any strategic initiatives; unfavorable publicity regarding the misuse of opioids; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; our ability to advance our strategic priorities, develop our product pipeline and continue to develop the market for QWO[®] and other products; and our ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. In addition, U.S. and international economic conditions, including consumer confidence and debt levels, inflation, taxation, changes in interest and currency exchange rates, international relations, capital and credit availability, the status of financial markets and institutions, the impact of and response to the ongoing COVID-19 pandemic and the impact of continued economic volatility, can materially affect our results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.



View original content to download multimedia: <https://www.prnewswire.com/news-releases/endo-and-smsna-launch-app-to-provide-peyronies-disease-self-assessment-tool-301660427.html>

SOURCE Endo International plc

Media Contacts: Endo: Linda Huss, media.relations@endo.com or SMSNA: Rachel Baxter, forpatients@smsna.org